Amgen Inc. ($AMGN) Stock Forecast: Up 5.0% Today

What is Amgen Inc.?

AMGN (Amgen Inc.) is a leading biotechnology company known for its innovative therapies in areas such as oncology, inflammation, and cardiovascular diseases. Today, the stock experienced a strong bullish movement in the market.

Why is Amgen Inc. going up?

AMGN stock is up 5.0% on Jun 11, 2026 19:11

• Amgen's bullish movement is linked to positive quarterly earnings that surpassed analyst estimates, highlighting the company's strong financial performance and growth prospects.
• The increased stake by Renaissance Group LLC indicates growing confidence in Amgen's future potential, particularly with key drivers like the obesity drug MariTide and a promising pipeline.
• Despite some caution from Wall Street analysts and insider selling by SVP Nancy A. Grygiel, the overall market sentiment towards Amgen remains positive, buoyed by the company's strategic acquisitions and successful drug developments in various therapeutic areas.

AMGN Price Chart

AMGN Technical Analysis

AMGN News

Gilead Sciences Inc Stock (GILD) Moved Up by 3.48% on Jun 11: Key Drivers Unveiled

Gilead Sciences' stock (GILD) rose by 3.48% due to positive developments in its pipeline, particularly in HIV treatments. Key drivers include positive Phase 3 results for islatravir/lenacapavir, FDA priority review for bictegravir/lenacapavir, and strong performance in existing HIV products. Additionally, positive Phase 3 results for Livdelzi in primary biliary cholangitis contributed to investor optimism, despite some setbacks in oncology.

https://www.tradingkey.com/news/market-movers/261961782-market-movers-gild-20260611

Caterpillar, Amgen Share Gains Lead Dow's 414-Point Jump

This article details how strong performances from Caterpillar and Amgen significantly contributed to the Dow Jones Industrial Average's 414-point increase. These gains suggest a positive day for industrial and biotechnology sectors within the broader market.

https://news.futunn.com/en/post/74474162/caterpillar-amgen-share-gains-lead-dow-s-414-point-jump

Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial

Takeda's AI-designed oral psoriasis drug, zasocitinib, significantly outperformed Bristol Myers Squibb’s Sotyktu in a Phase 3 study, achieving complete skin clearance in over 35% of patients at 16 weeks—more than 2.5 times the response rate of Sotyktu. These results position Takeda for an FDA filing for zasocitinib, which was acquired from Nimbus Therapeutics for $4 billion and targets the TYK2 protein to maintain IL-23 inhibition. The company plans to file drug applications with global health authorities starting this fiscal year, aiming to redefine the oral psoriasis market.

https://www.biospace.com/drug-development/takedas-ai-designed-pill-bests-bms-sotyktu-in-head-to-head-psoriasis-trial

Renaissance Group LLC Has $36.95 Million Stock Position in Amgen Inc. $AMGN

Renaissance Group LLC significantly increased its stake in Amgen Inc. during the fourth quarter, now holding 112,882 shares valued at approximately $36.95 million. Amgen represents 1.5% of the firm's portfolio. The company reported strong quarterly earnings, surpassing analyst estimates, and its obesity drug MariTide along with its broader pipeline are considered key growth drivers, despite mixed analyst ratings and an average target price of $354.12.

https://www.marketbeat.com/instant-alerts/filing-renaissance-group-llc-has-3695-million-stock-position-in-amgen-inc-amgn-2026-06-11/

Townsquare Capital LLC Sells 3,602 Shares of Amgen Inc. $AMGN

Townsquare Capital LLC reduced its stake in Amgen Inc. by 48.4% in the fourth quarter, selling 3,602 shares and holding 3,843 shares valued at approximately $1.26 million. Despite some recent positive news regarding its obesity drug MariTide and strong earnings, Wall Street analysts maintain a cautious "Hold" rating on AMGN with a consensus target price of $354.12. Other hedge funds also adjusted their positions, and insider selling by SVP Nancy A. Grygiel further impacted institutional ownership.

https://www.marketbeat.com/instant-alerts/filing-townsquare-capital-llc-sells-3602-shares-of-amgen-inc-amgn-2026-06-11/

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 17.4% Today

Amgen Inc. Price History

31.02.2026 - AMGN Stock was down 0.6%

• Amgen experienced a bearish movement despite reporting strong quarterly earnings and positive guidance for the fiscal year. This could be attributed to several factors:
• The market may have reacted negatively to the increased stake acquisitions by Mn Services Vermogensbeheer B.V. and Brookstone Capital Management, possibly signaling concerns about overvaluation or lack of confidence in the company's future performance.
• A recent report on the booming U.S. Rivaroxaban market might have shifted investor focus towards competitors in the cardiovascular space, leading to a sell-off of Amgen shares.
• Analyst warnings about potential setbacks for key launches or competitive pressures from generics in the biotechnology sector could have also contributed to the bearish sentiment surrounding Amgen's stock.
• Despite a recent stake acquisition, the overall market movement may have been influenced by broader industry trends and investor sentiment towards biotech companies rather than individual investment decisions.

07.00.2026 - AMGN Stock was up 5.0%

• Amgen's acquisition of Dark Blue Therapeutics for $840 million, aimed at expanding its oncology pipeline, has instilled optimism among investors regarding the company's strategic growth plans.
• The raise in Amgen's dividend to $2.52 indicates a sustainable payout ratio and a robust earnings growth projection, appealing to income-focused investors and contributing to the stock's performance.
• Comparatively, while Regeneron Pharmaceuticals has had quieter institutional appeal, Amgen's proactive stance in bolstering its portfolio and market standing has garnered positive attention.
• The general bullish outlook on Amgen is also influenced by the optimistic prospects within the broader biotech sector, where investors are acknowledging the potential driven by innovative treatments and strategic acquisitions for future growth.

05.00.2026 - AMGN Stock was down 1.4%

• The decline in Amgen's stock today may be linked to AbbVie's entry into the lung cancer drug market, potentially posing a competitive challenge for Amgen and affecting investor sentiment.
• Despite Amgen's positive quarterly earnings and dividend increase, market reaction might be influenced by the uncertainty surrounding the impact of AbbVie's new drug.
• Sizeable investments from D.A. Davidson & CO., Greenspring Advisors LLC, and Railway Pension Investments Ltd. indicate confidence in Amgen's future outlook. However, market caution could be attributed to the competitive landscape in lung cancer treatments.
• Overall, market sentiment towards Amgen remains optimistic, evident from analyst ratings and price targets. However, today's bearish trend suggests that investors are attentive to evolving competition within the biopharmaceutical sector.

01.04.2026 - AMGN Stock was down 5.4%

• Despite surpassing first-quarter earnings and revenue projections, Amgen experienced a 4.69% decline attributed to factors such as the FDA's potential withdrawal of the autoimmune drug Tavneos, a decrease in Prolia sales, and the revelation of IRS-related risks.
• The stock's downward movement was driven by these issues, overshadowing positive performances of other medications and encouraging pipeline updates, causing concern among investors and driving a bearish trend.
• Reductions in Amgen stakes by institutional investors like the New York State Teachers Retirement System and Danske Bank also played a role in pushing the stock price lower.
• The market's response underscores the significance of regulatory hurdles and patent expirations in the pharmaceutical sector, emphasizing the necessity for diversified drug portfolios and robust risk management practices for companies like Amgen.

01.04.2026 - AMGN Stock was down 6.4%

• Despite strong first-quarter results that surpassed earnings and revenue expectations, Amgen witnessed a notable downturn in its stock, opening with a 4.69% decrease.
• Market response was negative following the FDA's proposal to withdraw the autoimmune drug Tavneos, a decline in Prolia sales due to patent expiration, and the disclosure of a new IRS risk. These overshadowed the positive performance of other drugs and updates in the company's pipeline.
• Investor apprehension stemmed from these adverse developments, underscoring the significance of regulatory challenges and patent expirations in influencing stock performance, despite overall favorable financial results and growth prospects for Amgen.

04.01.2026 - AMGN Stock was up 4.3%

• Impressive annual product sales and a dispute with the FDA over Tavneos did not deter investors, as the stock soared to new heights.
• The company's wide economic moat, driven by its innovative drugs in cardiology and immunology, supported the bullish movement.
• Strong financial results for Q4 2025 and the full year, exceeding earnings expectations, along with an optimistic outlook for 2026, fueled investor confidence in Amgen's future growth potential.
• The market's positive reaction to Amgen's performance could also be attributed to the overall bullish sentiment in the biotechnology sector, as evidenced by Ayrmid's breakthrough in stem cell mobilization for gene therapies.

05.01.2026 - AMGN Stock was up 6.1%

• Today's positive movement in Amgen's stock could be a result of favorable investor sentiment following its strong quarterly earnings and increased dividend payout, indicating confidence in its product pipeline.
• The announcement of a SPAC merger by stem cell specialist PrimeGen US may have contributed to a positive market sentiment towards biotech firms, including Amgen, as non-traditional paths to public markets gain attention.
• Despite a maintained Underperform rating by Bank of America, referencing a shifted trial timeline for Amgen, the market appears more focused on the company's strong financial performance and growth prospects, overshadowing immediate concerns.
• Amgen's focus on diverse growth drivers, investments in research and development, and disciplined capital allocation during its recent earnings call likely reassured investors about the company's long-term potential for value creation, driving the positive movement.

06.00.2026 - AMGN Stock was up 2.3%

• AMGN's bullish movement can be attributed to its strategic acquisition of Dark Blue Therapeutics, a UK-based cancer drug developer, in a deal worth up to $840 million. This acquisition expands AMGN's oncology portfolio and strengthens its position in the biotechnology industry.
• The acquisition of Dark Blue Therapeutics adds an investigational small molecule targeting specific types of acute myeloid leukemia (AML) to AMGN's pipeline, showcasing the company's commitment to advancing oncology therapeutics.
• The market likely responded positively to the news as the acquisition aligns with AMGN's research focus on targeted protein degradation and leukemia therapeutics, demonstrating its dedication to enhancing its early oncology discovery efforts.
• Additionally, the promising preclinical data on the anti-cancer activity of the MLLT1/3 protein degrader acquired through this deal further fueled investor optimism in AMGN's future growth prospects in the oncology space.

04.01.2026 - AMGN Stock was up 7.4%

• Amgen's bullish movement can be attributed to its impressive Q4 2025 earnings report, exceeding expectations with robust growth across its portfolio and optimistic outlook for 2026.
• The company's refusal to pull the rare disease drug Tavneos from the market, despite FDA concerns, showcases Amgen's confidence in the drug's effectiveness and benefit-risk profile, potentially boosting investor confidence.
• Analysts raising price targets for Amgen indicate continued growth potential, supported by its diversified portfolio and focus on cardiovascular treatments.
• The overall positive sentiment towards Amgen, combined with its strategic growth initiatives and strong financial performance, likely contributed to the stock's bullish movement today.

04.01.2026 - AMGN Stock was up 6.9%

• Amgen's upward trend today is influenced by various factors:
• Analysts have a favorable view of the stock, as evidenced by a higher price target set by Royal Bank of Canada and strong Q4 earnings that surpassed predictions.
• The company's focus on cardiovascular treatments and groundbreaking drugs like Repatha has been instrumental in sustaining free cash flow and fostering growth opportunities.
• Despite a disagreement with the FDA regarding the inflammatory drug Tavneos, Amgen's substantial annual product sales demonstrate its resilience in the industry.
• Amgen's optimistic prospects are further supported by its broad economic moat and strategic position in critical therapeutic areas.

11.05.2026 - AMGN Stock was up 5.0%

• Amgen's bullish movement is linked to positive quarterly earnings that surpassed analyst estimates, highlighting the company's strong financial performance and growth prospects.
• The increased stake by Renaissance Group LLC indicates growing confidence in Amgen's future potential, particularly with key drivers like the obesity drug MariTide and a promising pipeline.
• Despite some caution from Wall Street analysts and insider selling by SVP Nancy A. Grygiel, the overall market sentiment towards Amgen remains positive, buoyed by the company's strategic acquisitions and successful drug developments in various therapeutic areas.

04.05.2026 - AMGN Stock was up 5.0%

• Amgen (AMGN) witnessed a significant increase in its stock price today, up by 3.0%.
• The positive momentum in the market was driven by surpassing earnings expectations and raising its FY2026 guidance, indicating strong financial performance and growth outlook.
• Notable institutional investors, including Cibc World Market Inc., Archvest Wealth Advisors Inc., and Avalon Capital Management, have been adding to their holdings of Amgen, reflecting confidence in its future trajectory.
• While concerns about certain products were raised in the valuation analysis, overall positive developments such as FDA breakthrough designations and European Commission approvals have contributed to the buoyant market sentiment.